Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre- and post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000-2006
Alberta, Canada introduced the Streptococcus pneumoniae seven valent conjugate vaccine (PCV7) program for children less than 2 years of age in September 2002. We determined the rates of invasive pneumococcal disease in Alberta, Canada 2 years pre- and 4 years post-PCV7 introduction (2000-2006) as well as the rates of antibiotic resistance and serotype distribution in this same time period. Overall, PCV7 serotypes decreased 61\% from 2000 to 2006. The greatest decrease in incidence of invasive pneumococcal disease occurred in children less than 2 years of age declining from a high of 96.7/100,000 (2000) to 25.8/100,000 (2006) (P\textless0.0001). Non-susceptibility of S. pneumoniae isolates to penicillin dropped significantly from 14\% in 2000 to 4.6\% in 2006 (P\textless0.0001). Non-susceptible erythromycin isolates also decreased from 8.8\% (2000) to 5.8\% (2006) (P=0.13). The introduction of PCV7 in Alberta, Canada has decreased the incidence of invasive pneumococcal disease in Alberta as well as resulting in a decrease in antibiotic resistance over this same time frame, principally for penicillin resistance.
%0 Journal Article
%1 tyrrell_serotypes_2009
%A Tyrrell, Gregory J
%A Lovgren, Marguerite
%A Chui, Natalie
%A Minion, Jessica
%A Garg, Sipi
%A Kellner, James D
%A Marrie, Thomas J
%D 2009
%J Vaccine
%K Adolescent, Adult, Aged, Canada, Child, Combination Erythromycin, Factors, Humans, Infant, Microbial Middle Penicillins, Pneumococcal Preschool, Sensitivity Serotyping, Streptococcus Tests, Time Vaccines, pneumoniae, {Trimethoprim-Sulfamethoxazole}
%N 27
%P 3553--3560
%R 10.1016/j.vaccine.2009.03.063
%T Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre- and post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000-2006
%U http://www.ncbi.nlm.nih.gov/pubmed/19464534
%V 27
%X Alberta, Canada introduced the Streptococcus pneumoniae seven valent conjugate vaccine (PCV7) program for children less than 2 years of age in September 2002. We determined the rates of invasive pneumococcal disease in Alberta, Canada 2 years pre- and 4 years post-PCV7 introduction (2000-2006) as well as the rates of antibiotic resistance and serotype distribution in this same time period. Overall, PCV7 serotypes decreased 61\% from 2000 to 2006. The greatest decrease in incidence of invasive pneumococcal disease occurred in children less than 2 years of age declining from a high of 96.7/100,000 (2000) to 25.8/100,000 (2006) (P\textless0.0001). Non-susceptibility of S. pneumoniae isolates to penicillin dropped significantly from 14\% in 2000 to 4.6\% in 2006 (P\textless0.0001). Non-susceptible erythromycin isolates also decreased from 8.8\% (2000) to 5.8\% (2006) (P=0.13). The introduction of PCV7 in Alberta, Canada has decreased the incidence of invasive pneumococcal disease in Alberta as well as resulting in a decrease in antibiotic resistance over this same time frame, principally for penicillin resistance.
@article{tyrrell_serotypes_2009,
abstract = {Alberta, Canada introduced the Streptococcus pneumoniae seven valent conjugate vaccine {(PCV7)} program for children less than 2 years of age in September 2002. We determined the rates of invasive pneumococcal disease in Alberta, Canada 2 years pre- and 4 years {post-PCV7} introduction (2000-2006) as well as the rates of antibiotic resistance and serotype distribution in this same time period. Overall, {PCV7} serotypes decreased 61\% from 2000 to 2006. The greatest decrease in incidence of invasive pneumococcal disease occurred in children less than 2 years of age declining from a high of 96.7/100,000 (2000) to 25.8/100,000 (2006) {(P{\textless}0.0001).} Non-susceptibility of S. pneumoniae isolates to penicillin dropped significantly from 14\% in 2000 to 4.6\% in 2006 {(P{\textless}0.0001).} Non-susceptible erythromycin isolates also decreased from 8.8\% (2000) to 5.8\% (2006) {(P=0.13).} The introduction of {PCV7} in Alberta, Canada has decreased the incidence of invasive pneumococcal disease in Alberta as well as resulting in a decrease in antibiotic resistance over this same time frame, principally for penicillin resistance.},
added-at = {2011-03-11T10:05:34.000+0100},
author = {Tyrrell, Gregory J and Lovgren, Marguerite and Chui, Natalie and Minion, Jessica and Garg, Sipi and Kellner, James D and Marrie, Thomas J},
biburl = {https://www.bibsonomy.org/bibtex/2ac03f03d53e2d3fe16f88cc5d6b4302c/jelias},
doi = {10.1016/j.vaccine.2009.03.063},
interhash = {d8fe5b99c8934f6d7f2ca15137cf7f84},
intrahash = {ac03f03d53e2d3fe16f88cc5d6b4302c},
issn = {{0264-410X}},
journal = {Vaccine},
keywords = {Adolescent, Adult, Aged, Canada, Child, Combination Erythromycin, Factors, Humans, Infant, Microbial Middle Penicillins, Pneumococcal Preschool, Sensitivity Serotyping, Streptococcus Tests, Time Vaccines, pneumoniae, {Trimethoprim-Sulfamethoxazole}},
month = jun,
note = {{PMID:} 19464534},
number = 27,
pages = {3553--3560},
timestamp = {2011-03-11T10:06:04.000+0100},
title = {Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre- and post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000-2006},
url = {http://www.ncbi.nlm.nih.gov/pubmed/19464534},
volume = 27,
year = 2009
}